The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial
Abstract
Background As survival among patients with cystic fibrosis has improved in recent decades, complications have become increasingly relevant. The most frequent complication is cystic-fibrosis-related diabetes. The recommended treatment is injected insulin, but some patients are treated with oral antidiabetic drugs to ease the treatment burden. We assessed the efficacy and safety of oral antidiabetic drugs.Methods We did a multicentre, open-label, comparative, randomised trial in 49 centres in Austria, France, Germany, and Italy. Eligible patients had cystic fibrosis, were older than 10 years, and had newly diagnosed diabetes. We used a central randomisation schedule derived from a Geigy random number table to assign patients 1:1 to receive insulin or repaglinide, stratified by sex and age (10-15 years or >15 years). The primary outcome was glycaemic control assessed by mean change in HbA 1c concentration from baseline after 24 months of treatment. Differences between groups were assessed by linear models. The primary and safety analyses were done in the modified intention-to-treat population (including patients who stopped treatment early because of lack of efficacy). This trial is registered with ClinicalTrials.gov, number NCT00662714.Findings We enrolled 34 patients in the repaglinide group and 41 in the insulin group, of whom 30 and 37, respectively, were included in the analyses. At 24 months, glycaemic control was similar in the repaglinide and insulin groups (mean change in HbA 1c concentration from baseline 0·2% [SD 0·7%], 1·7 mmol/mol [8·1 mmol/mol] with repaglinide vs -0·2% [1·3%], -2·7 mmol/mol, [14·5 mmol/mol] with insulin; mean difference between groups -0·4%, (95% CI -1·1 to 0·2 [-4·4 mmol/mol, -11·5 to 2·7], p=0·15). The most frequent adverse events were pulmonary events (43 [40%] of 107 in the repaglinide group and 60 [45%] of 133 in the insulin group), and the most frequent serious adverse events were pulmonary events leading to hospital admission (five [50%] of ten and seven [54%] of 13, respectively).Interpretation Repaglinide for glycaemic control in patients with cystic-fibrosis-related diabetes is as efficacious and safe as insulin.Funding Mukoviszidose eV, Vaincre la Mucoviscidose, ABCF Association, and Novo Nordisk.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Presentation may range from mild hyperglycemia to frank DM, ranging from 1% to 6%.1606,1607”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1607]
Citations
Cites
Spirometric Reference Values from a Sample of the General U.S. Population
HANKINSON, J. L., ODENCRANTZ, J. R., & FEDAN, K. B. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.1.9712108 · Cited by 4,206
Classification and Diagnosis of Diabetes
Fajans, S. S. (1990) · Medical Entomology and Zoology · Cited by 2,359
Clinical Care Guidelines for Cystic Fibrosis–Related Diabetes
Moran, A., Brunzell, C., Cohen, R. C., Katz, M., Marshall, B. C., Onady, G., Robinson, K. A., Sabadosa, K. A., Stecenko, A., Slovis, B., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1768 · Cited by 726
[Classification and diagnosis of diabetes].
Boulin (1953) · PubMed · Cited by 516
High treatment burden in adults with cystic fibrosis: challenges to disease self-management
Sawicki, G. S., Sellers, D. E., & Robinson, W. M. (2009) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2008.09.007 · Cited by 498
MILLA, C. E., WARWICK, W. J., & MORAN, A. (2000) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.162.3.9904075 · Cited by 367
Insulin Therapy to Improve BMI in Cystic Fibrosis–Related Diabetes Without Fasting Hyperglycemia
Moran, A., Pekow, P., Grover, P., Zorn, M., Slovis, B., Pilewski, J., Tullis, E., Liou, T. G., Allen, H., & the Cystic Fibrosis Related Diabetes Therapy Study Group (2009) · Diabetes Care · doi:10.2337/dc09-0585 · Cited by 240
Update on cystic fibrosis-related diabetes
Kelly, A., & Moran, A. (2013) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2013.02.008 · Cited by 203
Virk, S. A., Donaghue, K. C., Cho, Y. H., Benitez-Aguirre, P., Hing, S., Pryke, A., Chan, A., & Craig, M. E. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3604 · Cited by 109
Ziaian, T., Sawyer, M. G., Reynolds, K. E., Carbone, J. A., Clark, J. J., Baghurst, P., Couper, J., Kennedy, D., Martin, A. J., STAUGAS, R., et al. (2006) · Journal of Paediatrics and Child Health · doi:10.1111/j.1440-1754.2006.00943.x · Cited by 108
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Moran, A., Pillay, K., Becker, D., Granados, A., Hameed, S., & Acerini, C. L. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12732 · Cited by 171
ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis
Wilschanski, M. A., Munck, À., Carrión‐Jaramillo, E., Cipolli, M., Collins, S., Colombo, C., Declercq, D., Hatziagorou, E., Hulst, J. M., Kalnins, D., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.12.017 · Cited by 150
Ode, K. L., Ballman, M., Battezzati, A., Brennan, A., Chan, C. L., Hameed, S., Ismail, H. M., Kelly, A., Moran, A. M., Rabasa‐Lhoret, R., et al. (2022) · Pediatric Diabetes · doi:10.1111/pedi.13453 · Cited by 95
Diabetes of the exocrine pancreas
Wynne, K., Devereaux, B., & Dornhorst, A. (2018) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.14451 · Cited by 91
Metadata
- Authors
- Ballmann, M., Hubert, D., Assael, B. M., Staab, D., Hebestreit, A., Naehrlich, L., Nickolay, T., Prinz, N., Holl, R. W., Staden, U., Claßen, M., Schuster, A., Mellies, U., Posselt, H.-G., Wiebel, M., Rietschel, E., Stern, M., Teschler, H., Smaczny, C., Köhnlein, T., Wienhausen-Wilke, V., Claaß, A., Biedermann, T., Dockter, G., Köster, H., Hebestreit, H., Ballke, E.-H., Heuer, H.-E., Kamin, W., Küster, P., Szczepanski, R., Keller, K.-M., Generlich, H., Bresser, H.-G., Kopp, M., Herting, E., Feickert, H.-J., Hautz, J., Schilling, B., Meyer, E., Mall, M. A., Wiebicke, W., Tegtmeyer, F.-K., Honer, M., Mosnier-Pudar, H., Lenoir, G., Robert, J.-J., Kessler, L., Weiss, L., Nove-Josserand, R., Vantyghem, M.-C., Munck, A., Wizla, N., Leroy, S., Loeuille, G.-A., Serreau, R., Aissat, F., Thalhammer, G. H., Huttegger, I., Eichler, I., & Götz, M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Sorbonne Paris Cité (FR)
- University of Milan (IT)
- Humboldt-Universität zu Berlin (DE)
- University of Würzburg (DE)
- Justus-Liebig-Universität Gießen (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Universität Ulm (DE)
- Corresponding author
- Ballmann, Manfred
- ORCID
- Ballmann, Manfred
- Hubert, Dominique
- Assael, Baroukh M
- Staab, Doris
- Naehrlich, Lutz
- Prinz, Nicole
- Holl, Reinhard W
- Claßen, Martin
- Schuster, Antje
- Rietschel, Ernst
- Köster, Holger
- Hebestreit, Helge
- Kopp, Matthias
- Herting, Egbert
- Schilling, Birgit
- Mall, Marcus A
- Kessler, Laurence
- Weiss, Laurence
- Vantyghem, Marie-Christine
- Leroy, Sylvie
- Serreau, Raphaël
- Venue
- The Lancet Diabetes & Endocrinology
- Publisher
- Elsevier BV
- Published
- 2018-02
- Volume
- 6
- Issue
- 2
- Pages
- 114-121
- ISSN
- 2213-8587 (ISSN-L)
- OpenAlex
- W2775772713
- Cited by
- 71
- References
- 31
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 6 · 2023: 9 · 2022: 10 · 2021: 9 · 2020: 8 · 2019: 7 · 2018: 9
- FWCI
- 5.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet Diabetes & Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universität Ulm
- Association Vaincre la Mucoviscidose
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- repaglinide, insulin, cystic fibrosis-related diabetes, cystic fibrosis, newly diagnosed diabetes, oral antidiabetic drugs, glycemic control, HbA1c, pulmonary exacerbations, adverse events, treatment burden, adolescents and adults, type 2 diabetes treatment, drug safety and efficacy comparison, hospitalization, hospital readmission
- MeSH terms
- Adolescent, Adult, Blood Glucose, Carbamates, Child, Cystic Fibrosis, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Insulin, Male, Piperidines, Prognosis, Biomarkers, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. https://app.cochat.ai/papers/10.1016/s2213-8587(17)30400-x
- The paper
- Ballmann, M., Hubert, D., Assael, B. M., Staab, D., Hebestreit, A., Naehrlich, L., Nickolay, T., Prinz, N., Holl, R. W., Staden, U., Claßen, M., Schuster, A., Mellies, U., Posselt, H.-G., Wiebel, M., Rietschel, E., Stern, M., Teschler, H., Smaczny, C., . . . Götz, M. (2018). Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. The Lancet Diabetes & Endocrinology. https://doi.org/10.1016/s2213-8587(17)30400-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.